Olaplex Has 69% Gross Margin But Only 1.6% Operating Margin — Here's Why

If a CFO walked into your boardroom and told you they were running a 70% gross margin business, you'd assume profitability was a foregone conclusion. Beauty CPG with a 70% gross line is supposed to print money. That's the math: take 70 cents on the dollar, spend a normal amount on running the company, and operating margin lands in the high teens or low twenties. Lululemon does it (19.9% operating margin on a 56.6% gross). e.l.f. Beauty does it (12.0% on 71.2%). It's the standard play.

Olaplex is what happens when that math breaks. A 69.4% GAAP gross margin in fiscal 2025 (71.8% adjusted) — and a 1.6% operating margin. A 54-percentage-point gap between gross and operating. The product economics are still industry-elite. The company below them is not.

I run finance at 35+ ecommerce and CPG brands across $650M+ in managed revenue, and Olaplex is the textbook public example of a pattern I see in private beauty all the time: the brand that built its valuation on a gross margin story without ever proving its operating margin story. When the growth slowed, the gross margin held. The operating margin didn't. And once SG&A is calcified at 57% of revenue, you can't shrink it back to 25% on a phone call. This is a deep dive into what happened, what the data actually says, and what private beauty DTC brands should learn from it before they make the same bet.

The whole Olaplex story is below the gross line. Their product still makes money. Their company doesn't. That gap — between unit economics and operating economics — is the single most-underappreciated risk in DTC and CPG today. If you can't see your way to operating discipline at scale, your gross margin is just a really expensive vanity metric.

What does the 2021 IPO peak actually look like in the numbers?

Olaplex IPO'd in September 2021 at $19B+ implied market cap. It's worth pausing on what the financial picture looked like at that moment, because it explains everything that followed.

• Gross margin (FY2021): 79.19%. Top of the public DTC and CPG complex, beating even e.l.f. Beauty (63.8% that year).
• Operating margin (FY2021): 55.84%. Higher than Apple's. Higher than Microsoft's product margins for half the past decade.
• Adjusted gross margin (Q3 2021): 79.9%. Per the IPO-era 10-K, a level only reachable with a single-product, prestige-positioned, professionally-distributed brand with no real direct competition.

This was not a hype valuation. The math actually supported it at the time. A beauty CPG company posting 56% operating margins is a generational compounder if it's durable. The market priced durability, and at $19B, durability is the only thing the price made sense for.

The strategic question — the one I think the prior leadership team got wrong — was how to turn a 30-SKU, salon-led, prestige bond-builder into a brand with a $1B+ revenue trajectory. Aggressive specialty retail expansion was the answer. It's also the answer that broke the model.

How did the 2022-2024 collapse actually unfold?

The collapse is best understood in three layers stacked on top of each other: distribution overhang, salon channel decline, retail competition.

Distribution overhang

Olaplex went deep into Sephora and Ulta after the IPO. The brand was already in salon professional channels, and the retail push was supposed to be the volume engine that turned a $300M company into a $1B+ company. What it actually did was flood the prestige distribution and dilute scarcity. The brand became available everywhere — and at the same time, gray-market and arbitrage product crept onto Amazon, eroding price discipline. By 2023 the brand was on Sephora's discounting cadence, and by 2024 the original "you can only get this from your stylist" positioning was effectively dead.

Salon channel decline

The professional channel — Olaplex's birth channel — held up better than retail in absolute terms but not relative to expectations. Stylists who originally evangelized Olaplex began evangelizing competitors (K18 in particular). When the pro channel becomes a battleground rather than a moat, the entire narrative shifts.

Retail competition

K18, Redken Acidic Bonding Concentrate, Living Proof, Virtue, dupes from drugstore brands — by 2024 there were a dozen credible bond-builder products on shelf next to Olaplex, several at lower price points. None of them were as good (the IP is real). But "as good" doesn't matter when the average shopper at Sephora is walking past three options for the same use case at the same shelf.

Revenue tells the story:

Fiscal Year	Revenue (USD)	YoY Change
FY2022 (peak)	~$704M	—
FY2023	~$458M	-35%
FY2024	~$423M	-7.7%
FY2025	$423M	+0.1%
FY2026 guidance	$414-$435M	-2% to +3%

40% revenue decline from peak. Stabilization (not recovery) in FY2025. This is the revenue side of the picture. The cost side is where the real damage shows up.

Why did gross margin hold but operating margin collapse?

This is the most interesting question in the whole Olaplex story, and the answer is the entire thesis of the post.

Look at the five-year arc on the two margins side by side:

Fiscal Year	Gross Margin	Operating Margin	Gap (GM − OM)
FY2021	79.19%	55.84%	23.4 pts
FY2022	73.77%	51.74%	22.0 pts
FY2023	69.52%	23.61%	45.9 pts
FY2024	69.15%	15.84%	53.3 pts
FY2025	69.43%	1.64%	67.8 pts

Gross margin: down 9.76 points over five years. Operating margin: down 54.20 points. The gap between them more than tripled. Every dollar of structural change happened below the gross line.

Translated: the products kept making the same money per unit. The company that made them stopped making money per dollar of revenue. That is not a product problem, a category problem, or a competitive problem in any direct sense. That is a cost-structure problem in the purest form.

I make this distinction in client work all the time: gross margin tells you whether you have a business. Operating margin tells you whether you have a company. Olaplex has a business. The company around the business is the issue.

How big is the SG&A trap?

Time to put numbers on the cost structure.

• FY2025 SG&A: $243.1M. 57.5% of revenue.
• FY2024 SG&A: $181.7M. 42.9% of revenue (on similar revenue).
• YoY SG&A growth: +33.8% on flat revenue.

Let me say that again: SG&A grew 33.8% in a year when revenue grew 0.1%. That is the entire bridge from a still-respectable 15.8% operating margin in FY2024 to a barely-positive 1.6% operating margin in FY2025. It's not subtle.

The drivers, per the FY2025 10-K and Q4 commentary: front-loaded marketing investment behind the "Bonds & Beyond" platform, infrastructure for the Pervala Bioscience acquisition, innovation pipeline build-out, plus the public-company overhead that doesn't compress when revenue does. Every one of these is a defensible spend on its own. Stacked together on a revenue base that was supposed to be $700M and is now $423M, they crush operating margin.

For context against the full public DTC dataset (n=15 brands with 2025 data):

• Lululemon SG&A: 36.6% of revenue. Operating margin: 19.9%.
• Yeti SG&A: 46.0% of revenue. Operating margin: 11.4%.
• e.l.f. Beauty SG&A: 59.2% of revenue. Operating margin: 12.0% (gross is 71.2%).
• Olaplex SG&A: 57.5% of revenue. Operating margin: 1.6%.
• Beyond Meat SG&A: 79.0% of revenue. Operating margin: -121.1%.

Olaplex's SG&A intensity is comparable to e.l.f. — both have ~70% gross margins and SG&A in the high 50s. The difference: e.l.f. is growing into its SG&A (revenue up double-digits, operating margin holding at 12%). Olaplex isn't (revenue flat, operating margin compressed 14 points YoY).

Read more on the structural pattern: SG&A as % of revenue in public DTC, 2026 benchmarks.

Why is working capital also broken at Olaplex?

Most people writing about Olaplex stop at the income statement. The balance sheet is just as instructive — and arguably worse, because cash conversion cycle is the metric a lender or buyer cares about most.

FY2025 working capital snapshot:

Metric	Olaplex FY2025	e.l.f. Beauty FY2025	Lululemon FY2026
Inventory days	170.0	180.8	128.8
Days sales outstanding (DSO)	25.0	35.0	n/a
Days payable outstanding (DPO)	22.9	69.7	25.1
Cash conversion cycle (CCC)	172.1	146.1	~104

The line that should jump out: 22.9 days payable outstanding. Olaplex pays its suppliers in 23 days. e.l.f. pays in 70 days. Lululemon in 25. The e.l.f. comparison is the most telling because the gross margin profile is nearly identical — but e.l.f. uses payables as a free working-capital lever and Olaplex doesn't.

If Olaplex extended payables to e.l.f.'s 70-day level, the cash conversion cycle would drop from 172 days to roughly 125 days. That's tens of millions of dollars in working capital freed up. It's the cheapest financing in the building, and it's not being used.

The 170 inventory days is a separate problem. For a 30-SKU brand with stable demand, sitting on nearly six months of inventory is generous. To management's credit, inventory dropped from $75.2M to $60.2M during FY2025 — directionally right. But the run-rate is still slow for the category, and the cash benefit of inventory normalization is limited if payables remain compressed.

Combined picture: Olaplex is running a high-gross-margin product business with mid-tier operating discipline and bottom-tier working capital management. That's not a Henkel-takeout-at-$2.06 valuation by accident.

For more on the metric: Cash conversion cycle benchmarks across public DTC, 2026.

Is there a recovery playbook — or is this terminal?

The question I'd ask if a private brand walked in with this margin profile is: what would have to be true for operating margin to recover to 15-20%?

Three things, in order of difficulty:

1. Stabilize revenue at $400-450M and hold

Don't grow into the SG&A. Cut the SG&A back to fit the revenue. That's a $50-70M absolute cost-out from the $243M base — call it 20-25% of SG&A — to get operating margin back to a 12-15% zone on stable revenue. Hard but possible. Most cost-out programs of that size take 12-18 months and meaningfully impact morale, talent retention, and innovation pipeline.

2. Restore the channel mix

Pro is +5.5% YoY. DTC is +3.1%. Specialty retail is -8.3%. The signal is clear: lean into pro, lean into DTC, accept a smaller specialty retail footprint as a reset. Henkel as the new owner has the salon distribution muscle to make this real (it's literally what they do with Schwarzkopf). This is the most defensible part of the recovery thesis.

3. Reposition the brand without reigniting price wars

The hardest part. Olaplex has to recover prestige perception without raising prices into a market where K18 and others are at parity or below. The "Bonds & Beyond" platform is the attempt — broaden the line, reanchor the science narrative, lean into the IP. Whether it works is a 24-36 month question, not a 12-month question.

My honest take: under public-company pressure, this was unlikely to recover on the original timeline. Under Henkel ownership, it has a fighting chance. Henkel doesn't have to optimize for quarterly earnings, can fund the rebuild on its own balance sheet, and has the salon distribution that should have been the moat in the first place. The 1.6% operating margin in FY2025 is the floor of the public-company era — not necessarily the floor of the brand.

For the broader pattern: Hidden operators in public DTC: brands with strong gross margin, weak operating margin.

What should private beauty DTC actually take from this?

I work with a lot of private beauty and personal care brands in the $5M-$150M range, and I've seen the Olaplex pattern take root in a half-dozen of them over the past three years. Here are the lessons that translate.

Lesson 1: A 70% gross margin gives you room, not a result

I've said this in client meetings probably 200 times: gross margin tells you whether you have permission to compete. It doesn't tell you whether you'll win. A brand with a 70% gross margin and a 60% SG&A is barely operating. A brand with a 50% gross margin and a 35% SG&A is making 15% operating margin. Cost discipline is independent of gross margin discipline, and you have to win both. This is what I told a beauty client last year when they pulled an 80% gross margin: "great, you can pull off 80, 85 gross. Now show me what you do with it." If the answer is "spend 60% on SG&A," you don't actually have a beauty business — you have an expensive marketing experiment with great unit economics.

Lesson 2: Don't build infrastructure for the revenue you wish you had

Olaplex built the cost structure of a $700M company. They now operate a $423M company on the same overhead. The mistake was running the SG&A build ahead of revenue durability rather than behind it. In private brand work, the rule I use: SG&A capacity additions lag revenue by at least 6-12 months. Don't hire the head of innovation when revenue is flat for two quarters. Don't build the international team before you've proven the domestic playbook. The cost of being slightly under-resourced for a year is a fraction of the cost of having to right-size three years later.

Lesson 3: Distribution width is not distribution quality

The single biggest strategic error of post-IPO Olaplex was treating specialty retail expansion as a volume play instead of a positioning decision. Every door you add changes how the brand is perceived. Sephora and Ulta give you reach; they also give you discounting cadence, gray-market exposure, and parity-shelf competition. For private beauty < $50M, the lesson is: protect the channel mix that produces your gross margin. If your gross margin comes from professional or prestige positioning, expanding into mass kills the goose. Olaplex didn't fully kill the goose — Henkel is buying a real brand — but it badly wounded it.

Lesson 4: Working capital is the cheapest financing in the building

The 22.9-day payables figure at a $423M brand is borderline operationally negligent. I've taken brands from 30-day payables to 60-day payables in 90 days through nothing more than disciplined vendor renegotiation and matched cash terms. The capital this frees is significantly cheaper than any debt facility, any equity raise, and any form of growth financing. If your CFO isn't running this lever, your CFO isn't running the balance sheet — they're running the income statement and hoping the rest figures itself out.

Lesson 5: The market punishes the gap, not the metric

The gap between gross margin and operating margin is the metric the public market actually cares about. Olaplex's $19B IPO valuation didn't come back when gross margin held at 69% — it stayed gone because the gap kept widening. For private brands considering exit, the buyer is going to underwrite to operating margin, not gross margin. A 65% gross / 18% operating brand is far more valuable than a 75% gross / 4% operating brand at the same revenue. Underwrite that gap from the day you start the company, not the year before you sell.

Frequently Asked Questions

What is Olaplex's gross margin in 2026?

Olaplex reported a 69.4% GAAP gross margin and 71.8% adjusted gross margin in fiscal 2025 (10-K filed March 2026). That puts it in the top decile of public DTC and CPG brands — only e.l.f. Beauty (71.2%) is comparable on raw gross margin among publicly traded beauty companies. The structural product economics never broke; gross margin held within 30 basis points of fiscal 2024 even as revenue dropped from a peak of $704M to $423M.

Why is Olaplex's operating margin so low if gross margin is so high?

Olaplex's operating margin compressed to 1.64% in fiscal 2025 — a 54-percentage-point gap below its gross margin — because SG&A expanded to 57.5% of revenue ($243.1M) while revenue stayed flat at $423M. SG&A grew 33.8% year-over-year (from $181.7M) on rising marketing, innovation, and infrastructure spend, even as revenue declined 7.7% cumulatively from 2023. The product economics are pristine; the cost-to-distribute structure no longer scales to the smaller revenue base.

What happened to Olaplex's revenue from 2022 to 2026?

Peak revenue was $704M in fiscal 2022. By fiscal 2025, revenue had dropped to $423M — a 40% decline over three years. The decline was driven by specialty retail over-distribution (specialty retail down 8.3% in fiscal 2025 alone, after a deeper 2023-2024 collapse) compounded by competition from K18, Redken, and a wave of "bond builder" dupes. The professional salon channel (+5.5% in FY2025) and DTC (+3.1%) held up; the retail channel was the structural problem. Henkel acquired Olaplex in early 2026 at $2.06 per share, valuing the company at under $1.4B versus a $19B IPO valuation in 2021.

What does Olaplex's working capital look like in 2026?

Olaplex's cash conversion cycle was 172.1 days in fiscal 2025 — among the slowest in our 19-brand public DTC dataset. The breakdown: 170 inventory days, 25 days sales outstanding, and only 22.9 days payable outstanding. That payables figure is what most people miss — a brand with $243M in SG&A and $130M in inventory on the balance sheet is paying suppliers in 23 days while collecting in 25 and holding inventory for 170. The cash gap is structural. Inventory did improve to $60.2M by year-end 2025 (from $75.2M), so management is actively working the problem, but the run-rate is still elite-tier slow.

What can private beauty DTC brands learn from Olaplex?

Three lessons. First: a 70% gross margin is necessary but not sufficient — it gives you room to compete, but it does not guarantee profitability if your cost structure expands faster than your revenue base. Second: the "we'll grow into the SG&A" bet only works if revenue is actually growing. Olaplex built infrastructure for a $700M company and now operates a $423M company on the same overhead base. Third: distribution width is not the same as distribution quality. Aggressive specialty retail expansion diluted the prestige positioning that produced the gross margin in the first place. The lesson for sub-$100M private beauty brands: protect the channel mix that produces your gross margin before you chase volume that erodes it.

Sources

• Olaplex Holdings, Inc. 10-K filing for fiscal year ended December 31, 2025 (SEC EDGAR, filed March 2026)
• Olaplex Holdings Q4 and FY2025 earnings release (March 2026), via Olaplex Investor Relations
• Olaplex Q3 2021 earnings release (IPO-era, S-1 reference): adjusted gross margin 79.9%
• SEC EDGAR full historical filings, ticker OLPX (CIK 0001868726)
• Beauty Matter, "Olaplex's IPO Undoing and Henkel's Second Chance at a Turnaround" (2026)
• Investing.com Q4 2025 earnings recap (April 2026)
• Eightx public DTC benchmark dataset, fiscal 2025 / fiscal 2026 (n=19 publicly-traded ecommerce, DTC, and CPG brands), aggregated from SEC EDGAR 10-K data